Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-001
- Development stage
- Preclinical
- Lead developer
- C-BIOMEX
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
CBT-001 is a peptide receptor radionuclide therapy (PRRT) being developed by C-BIOMEX for the treatment of cancers overexpressing carbonic anhydrase IX (CAIX), with a primary focus on clear cell renal cell carcinoma (ccRCC). The drug consists of a proprietary peptide ligand, discovered using C-BIOMEX's CUSTM platform, conjugated to the beta-emitting radioisotope Lutetium-177. CBT-001 specifically targets and binds to CAIX on the surface of tumor cells, delivering cytotoxic radiation that induces DNA damage and subsequent cell death. Preclinical studies are being conducted in collaboration with MD Anderson Cancer Center to support an anticipated Investigational New Drug (IND) application with the FDA.
- Other names
- Lutetium (177Lu) CBT-001177Lu-CBT-001
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on CBT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBT-001.